4BASEBIO UK SOCIETAS (LSE:4BB) — Stock Price
4BASEBIO UK SOCIETAS (LSE:4BB) is currently trading at GBX562.50 GBX, up 0.00% today. Over the past 52 weeks, shares have ranged between GBX435.00 and GBX795.00. This page tracks 4BASEBIO UK SOCIETAS's live share price on the LSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 4BB company net worth.
4BASEBIO UK SOCIETAS (4BB) Stock Price Chart — Daily History & Trading Volume
The chart below tracks 4BASEBIO UK SOCIETAS's daily closing share price and trading volume on the LSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
4BASEBIO UK SOCIETAS Income Statement — Revenue, Profit & Earnings by Year
4BASEBIO UK SOCIETAS's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | GBX1.69 Million | GBX933.00K | GBX506.00K | GBX268.00K | GBX338.00K |
| Cost of Revenue | GBX1.15 Million | GBX303.00K | GBX166.00K | GBX29.00K | GBX69.00K |
| Gross Profit | GBX548.00K | GBX630.00K | GBX340.00K | GBX239.00K | GBX269.00K |
| Research & Development | GBX5.12 Million | GBX4.68 Million | GBX3.56 Million | GBX2.08 Million | GBX1.62 Million |
| SG&A | GBX1.44 Million | GBX1.41 Million | GBX1.26 Million | GBX2.71 Million | GBX1.73 Million |
| Total Operating Expenses | GBX17.27 Million | GBX12.67 Million | GBX8.39 Million | GBX6.08 Million | GBX3.80 Million |
| Operating Income | GBX-16.73 Million | GBX-12.04 Million | GBX-8.05 Million | GBX-5.84 Million | GBX-3.53 Million |
| EBITDA | GBX-15.58 Million | GBX-10.97 Million | GBX-7.34 Million | GBX-5.41 Million | GBX-3.21 Million |
| EBIT | GBX-16.73 Million | GBX-11.90 Million | GBX-8.05 Million | GBX-5.84 Million | GBX-3.53 Million |
| Interest Expense | GBX887.00K | GBX752.00K | GBX302.00K | GBX89.00K | GBX113.00K |
| Income Before Tax | GBX-17.60 Million | GBX-12.65 Million | GBX-8.35 Million | GBX-5.93 Million | GBX-3.64 Million |
| Income Tax Expense | GBX-698.00K | GBX-321.00K | GBX-689.00K | GBX-779.00K | GBX-405.00K |
| Net Income | GBX-16.91 Million | GBX-12.33 Million | GBX-7.67 Million | GBX-5.15 Million | GBX-3.23 Million |
4BASEBIO UK SOCIETAS Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes 4BASEBIO UK SOCIETAS's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | GBX29.55 Million | GBX44.73 Million | GBX11.92 Million | GBX11.69 Million | GBX14.70 Million |
| Total Current Assets | GBX20.66 Million | GBX36.89 Million | GBX5.02 Million | GBX5.90 Million | GBX10.64 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | GBX225.00K | GBX236.00K | GBX240.00K | GBX228.00K |
| Net Receivables | GBX289.00K | GBX283.00K | GBX107.00K | GBX54.00K | GBX46.00K |
| Inventory | GBX657.00K | GBX374.00K | GBX332.00K | GBX133.00K | GBX156.00K |
| Property, Plant & Equipment | — | — | — | — | GBX2.76 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | GBX19.44 Million | GBX18.35 Million | GBX12.41 Million | GBX4.57 Million | GBX3.01 Million |
| Total Current Liabilities | GBX2.83 Million | GBX3.27 Million | GBX2.28 Million | GBX1.52 Million | GBX1.52 Million |
| Long-term Debt | GBX15.86 Million | GBX14.29 Million | GBX9.30 Million | GBX2.41 Million | GBX860.00K |
| Net Debt | GBX-1.30 Million | GBX-19.39 Million | GBX7.39 Million | GBX-1.00 Million | GBX-7.83 Million |
| Total Stockholder Equity | GBX10.11 Million | GBX26.38 Million | GBX-492.00K | GBX7.12 Million | GBX11.70 Million |
| Retained Earnings | GBX-54.94 Million | GBX-38.72 Million | GBX-26.39 Million | GBX-18.73 Million | GBX-13.57 Million |
4BASEBIO UK SOCIETAS Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how 4BASEBIO UK SOCIETAS generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | GBX-14.75 Million | GBX-10.74 Million | GBX-6.18 Million | GBX-4.70 Million | GBX-2.74 Million |
| Capital Expenditures | GBX458.00K | GBX1.57 Million | GBX1.49 Million | GBX1.94 Million | GBX1.51 Million |
| Free Cash Flow | GBX-15.21 Million | GBX-12.31 Million | GBX-7.67 Million | GBX-6.64 Million | GBX-4.25 Million |
| Investing Cash Flow | GBX-1.64 Million | GBX-1.57 Million | GBX-1.49 Million | GBX-1.94 Million | GBX-1.51 Million |
| Financing Cash Flow | GBX-369.00K | GBX43.87 Million | GBX6.42 Million | GBX1.24 Million | GBX-467.00K |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | GBX288.00K | GBX334.00K | GBX223.00K | GBX128.00K | GBX80.00K |
| Depreciation | GBX1.15 Million | GBX933.00K | GBX709.00K | GBX431.00K | GBX320.00K |
| Change in Cash | GBX-16.80 Million | GBX31.54 Million | GBX-1.28 Million | GBX-5.24 Million | GBX-5.42 Million |
4BASEBIO UK SOCIETAS Earnings History — EPS Actual vs. Analyst Estimates
Track 4BASEBIO UK SOCIETAS's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 25, 2026 | — | — | — |
| Feb 25, 2026 | 0.00 | -0.67 | +100.00% |
| Sep 29, 2025 | -0.50 | 0.00 | — |
| May 30, 2025 | -0.49 | 0.00 | — |
| Sep 27, 2024 | -0.45 | 0.00 | — |
| May 11, 2023 | -0.22 | — | — |
| Sep 30, 2022 | -0.20 | — | — |
| Jun 09, 2022 | -0.13 | 0.00 | — |